Literature DB >> 12059871

Electroretinographic oscillatory potentials in insulin-dependent diabetes patients: A long-term follow-up.

Maria Vadalà1, Mario Anastasi, Gaetano Lodato, Salvatore Cillino.   

Abstract

PURPOSE: The aim of this research was to study the relevance of long-term follow-up of electroretinographic oscillatory potentials (OPs) in predicting the onset of minimal non-proliferative diabetic retinopathy in insulin-dependent diabetes patients.
METHODS: A total of 80 insulin-dependent diabetics, with normal fundi and normal OPs at first examination, were followed prospectively for 10 years. Oscillatory potentials were measured and fundus examinations performed once or twice per year.
RESULTS: During follow-up, 35% of patients developed diabetic retinopathy after a mean disease duration of 12 +/- 2 years. A decrease in OP amplitudes was seen in 46% of this group, but reductions were also seen in the 25% of patients whose fundi remained normal. Statistical analysis of best-fit survival curves shows a significant difference (p < 0.001) in the point of Kaplan-Meiers' curve maximal linearity (TmaxS).
CONCLUSIONS: It appears that eyes with reduced OP amplitude have a greater probability of developing diabetic retinopathy. Subnormal OP amplitudes are not proof of real concomitant visible vascular damage, but may reflect a predisposition to functional neurosensorial disorder.

Entities:  

Mesh:

Year:  2002        PMID: 12059871     DOI: 10.1034/j.1600-0420.2002.800314.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  19 in total

1.  Human oscillatory potentials: intensity-dependence of timing and amplitude.

Authors:  Heather A Hancock; Timothy W Kraft
Journal:  Doc Ophthalmol       Date:  2008-04-30       Impact factor: 2.379

2.  Selective inner retinal dysfunction in growth hormone transgenic mice.

Authors:  Brent T Martin; Edward O List; John J Kopchick; Yves Sauvé; Steve Harvey
Journal:  Growth Horm IGF Res       Date:  2011-06-25       Impact factor: 2.372

3.  Baseline haemoglobin A1c influences retinal function after long-term insulin pump therapy.

Authors:  Oliver N Klefter; Stig K Holfort; Michael Larsen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-25       Impact factor: 3.117

4.  Protective Effects of Adeno-associated Virus Mediated Brain-derived Neurotrophic Factor Expression on Retinal Ganglion Cells in Diabetic Rats.

Authors:  Yan Gong; Zhan-Ping Chang; Ruo-Tong Ren; Shi-Hui Wei; Huan-Fen Zhou; Xiao-Fei Chen; Bao-Ke Hou; Xin Jin; Mao-Nian Zhang
Journal:  Cell Mol Neurobiol       Date:  2012-02-02       Impact factor: 5.046

5.  Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats.

Authors:  Lokesh Kumar Bhatt; Veeranjaneyulu Addepalli
Journal:  Am J Transl Res       Date:  2010-02-12       Impact factor: 4.060

6.  Oscillatory potentials and the b-Wave: partial masking and interdependence in dark adaptation and diabetes in the rat.

Authors:  C J Layton; R Safa; N N Osborne
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-31       Impact factor: 3.117

7.  Early local functional changes in the human diabetic retina: a global flash multifocal electroretinogram study.

Authors:  Jenny C Y Lung; Peter G Swann; Henry H L Chan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-12       Impact factor: 3.117

Review 8.  Visual dysfunction associated with diabetic retinopathy.

Authors:  Gregory R Jackson; Alistair J Barber
Journal:  Curr Diab Rep       Date:  2010-10       Impact factor: 4.810

9.  The effects of early diabetes on inner retinal neurons.

Authors:  Erika D Eggers; Teresia A Carreon
Journal:  Vis Neurosci       Date:  2020-09-16       Impact factor: 3.241

10.  Protection of exendin-4 analogue in early experimental diabetic retinopathy.

Authors:  Yu Zhang; Qingping Wang; Jingfa Zhang; Xia Lei; Guo-Tong Xu; Wen Ye
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-16       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.